The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 12, 2023

Filed:

Aug. 31, 2022
Applicant:

Amgen Inc., Thousand Oaks, CA (US);

Inventors:

Nathan Bennette, Thousand Oaks, CA (US);

William Brett Caldwell, Thousand Oaks, CA (US);

Christi Hostetler, Thousand Oaks, CA (US);

Kazden Ingram, Thousand Oaks, CA (US);

Dory King, Thousand Oaks, CA (US);

Kyle Kyburz, Thousand Oaks, CA (US);

Alison Viles, Thousand Oaks, CA (US);

Assignee:

AMGEN INC., Thousand Oaks, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 9/20 (2006.01); A61K 31/4035 (2006.01); A61K 9/00 (2006.01); A61K 9/28 (2006.01);
U.S. Cl.
CPC ...
A61K 31/4035 (2013.01); A61K 9/0065 (2013.01); A61K 9/2009 (2013.01); A61K 9/2054 (2013.01); A61K 9/2086 (2013.01); A61K 9/2853 (2013.01); A61K 9/2866 (2013.01);
Abstract

Provided herein are oral dosage forms comprising a) a core tablet comprising (i) a drug layer comprising apremilast and hypromellose acetate succinate (HPMCAS) in an amorphous solid dispersion; and (ii) a swellable layer comprising one or more swellable polymers; and b) a coating layer disposed on the core tablet, wherein the oral dosage form surface comprises at least one drug release orifice. The disclosed oral dosage forms provide once-a-day dosing of apremilast and are suitable for treating diseases or disorders ameliorated by inhibiting phosphodiesterase subtype IV (PDE4).


Find Patent Forward Citations

Loading…